Table 1 Demographic and clinical characteristics of the study participants at inclusion
Healthy controls (n = 65) | BD patients (n = 80) | p†| |
|---|---|---|---|
Age (years) | 34 (25, 46) | 31 (24, 45) | – |
Sex (M/F) | 34/31 | 49/31 | – |
Metabolic parameters | |||
 BMI (kg/m2) | 23.03 (21.76, 24.53) | 23.98 (22.29, 26.79) | 0.064 |
 SBP (mmHg) | 120 (112, 135) | 126 (120, 142) | 0.031* |
 DBP (mmHg) | 80 (70, 85) | 85 (71, 88) | 0.049* |
 TG (mmol/L) | 1.03 (0.71, 1.76) | 1.42 (0.92, 1.83) | 0.105 |
 CHO (mmol/L) | 4.31 (3.83, 5.42) | 4.70 (4.33, 5.53) | 0.026* |
 HDL-c (mmol/L) | 1.24 (1.05, 1.47) | 1.29 (1.09, 1.48) | 0.618 |
 LDL-c (mmol/L) | 3.05 (2.62, 3.65) | 3.14 (2.85, 3.64) | 0.24 |
 apo A(g/L) | 1.37 (1.23, 1.49) | 1.51 (1.35, 1.58) | 0.004** |
 apo B(g/L) | 0.92 (0.77, 1.12) | 0.88 (0.75, 1.02) | 0.529 |
 FBG (mmol/L) | 5.06 (4.47, 5.34) | 4.89 (4.49, 5.67) | 0.808 |
Comorbidities | |||
 Obesity, n (%) | 6 (9.2%) | 13 (16.3%) | 0.159 |
 Dyslipidemia, n (%) | 25 (38.5%) | 30 (37.5%) | 0.316 |
 IGM, n (%) | 5 (7.7%) | 6 (7.6%) | 0.603 |
Medications | |||
 SGA+ MS, n (%) | – | 23 (28.8%) | – |
 SGA+ AED, n (%) | – | 22 (27.5%) | – |
 SGA+ MS+ AED, n (%) | – | 12 (15%) | – |
 Drug-naive, n (%) | – | 23 (28.8%) | – |